STOCK TITAN

InMed disclosure names Mentari in 5.6% stake report

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. (INM) is identified as issuer for this analysis, but the supplied Schedule 13G text identifies Mentari Therapeutics, Inc. as the issuer whose shares are reported. Commodore Capital LP, Commodore Capital Master LP, Michael Kramarz and Robert Egen Atkinson each report the same beneficial ownership position of 2,977,630 Mentari common shares, or 5.6%, as of November 6, 2026. The position carries shared voting and dispositive power; each filer reports zero sole voting and dispositive power. The percentage is based on 52,813,914 Mentari common shares reported issued and outstanding on that date.

Beneficial ownership 2,977,630 shares Same reported position for each reporting person; Mentari Therapeutics common stock, as of November 6, 2026
Ownership percentage 5.6% Mentari Therapeutics common stock; based on shares reported outstanding as of November 6, 2026
Shares outstanding 52,813,914 shares Mentari Therapeutics common stock reported issued and outstanding as of November 6, 2026
beneficially own regulatory
"may be deemed to beneficially own these securities"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting power regulatory
"Shared Voting Power 2,977,630"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 2,977,630"
investment discretion regulatory
"exercise investment discretion with respect to these securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What shareholding does the INM Schedule 13G text report?

The statement text identifies Mentari Therapeutics, Inc.—not InMed Pharmaceuticals—as the issuer and reports 2,977,630 shares, or 5.6%, as the same beneficial ownership position for each of the four reporting persons.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





587157108

(CUSIP Number)
11/06/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Commodore Capital LP
Signature:Michael Kramarz
Name/Title:Michael Kramarz
Date:11/13/2026
Commodore Capital Master LP
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:11/13/2026
Robert Egen Atkinson
Signature:Robert Egen Atkinson
Name/Title:Authorized Signatory
Date:11/13/2026
Michael Kramarz
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:11/13/2026
Exhibit Information

Exhibit 1: Joint Filing Agreement

Keep reading